


## The Ability of N-Glycan Inhibitors to Suppress Pancreatic Cancer Growth

Janine Hsu<sup>1</sup>, Chin-Chun Chang<sup>2</sup>, Chun-Mei Hu<sup>2</sup>, Wen-Hwa Lee<sup>2</sup>. Genomics Research Center, Academia Sinica.







### Abstract


N-glycan inhibitors are potent drugs for suppressing pancreatic cancer. Their ability to block the pathway of the production of complex type N-glycans allows the N-glycosylation distribution in pancreatic cancer cells to alter in a way that is unfavorable for cancer growth. Our research focuses on the effects N-glycan inhibitors have on the viability and sphere formation of pancreatic cancer cell lines. Our experiments demonstrate that N-glycan inhibitors can reduce cell viability of cancer cells, although they will also reduce cell viability of fibroblasts and normal pancreatic cells. However, N-glycan inhibitors are effective in suppressing sphere formation of cancer cells. This result establishes altering N-glycosylation distribution as a promising treatment for pancreatic cancer.


### Introduction



#### **Glycosylation Alteration during Cancer Transformation**









### Results

# N-Glycan Inhibitors Suppress Sphere Formation and Viability of Pancreatic Cancer Cells




Result: N-glycan inhibitor A is the least effective in killing pancreatic cancer cells



Result: N-glycan inhibitor A is the most effective in suppressing sphere formation of pancreatic cancer cells

## N-Glycan Inhibitor A Suppresses Sphere Formation in Pancreatic Cancer Cells



Result: N-glycan inhibitor A can suppress sphere formation of pancreatic cancer cells in three different cell lines

### Conclusion

All the N-glycan inhibitors can suppress sphere formation and viability of pancreatic cancer cells. N-glycan inhibitor A has the highest  $IC_{50}$  for both normal and cancer cells, suggesting that it has the lowest level of toxicity compared to the other inhibitors. It is also the most effective in inhibiting cancer stemness.

### Discussion

Previous research has shown that N-glycan inhibitors can suppress liver cancer growth. In our study, we successfully demonstrated that N-glycan inhibitors can also inhibit cancer development in pancreatic cancer. However, what effects the decreased amount of complex type N-glycans have on the expression of proteins and how that leads to killing cancer cells require further study. Future research will focus on finding out the proteins affected by the inhibitors and developing new drugs that only target the specific proteins that need to have their N-glycosylation distribution altered to suppress cancer development.

### References

- Chen, Wei-An, et al. "Harnessing natural-product-inspired combinatorial chemistry and computation-guided synthesis to develop N-glycan modulators as anticancer agents." Chemical Science, 13, 2022, 6233-6243.
- Diniz, Francisca, et al. "Glycans as Targets for Drug Delivery in Cancer." Cancers, vol. 14, no. 4, Feb. 2022, p. 911.
- . Lu, H., Xiao, K., Tian, Z. "Benchmark of site and structure-specific quantitative tissue N-glycoproteomics for discovery of potential N-glycoprotein markers: a case study of pancreatic cancer. Glycoconjugate Journal, 38, 2021, 213-231.
- Munkley, Jennifer. "The glycosylation landscape of pancreatic cancer." Oncology letters, vol. 17, 3, 2019, 2569-2575.